European Research Council grant · Finished
NASHTARGET Validation of a new drug target in non-alcoholic steatohepatitis
- Coordinator
- Kobenhavns Universitet, Denmark
- Runs
- 1 June 2023 to 30 November 2024
- Status
- Finished
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101123183
What the project is doing
In the project's own words, from its summary on CORDIS.
This research focuses on the increasing prevalence of metabolic liver disease, specifically non-alcoholic steatohepatitis (NASH), which is driven by obesity, diabetes, and its related causal connections. NASH is a significant medical challenge with no approved treatments, causing a substantial economic burden. The project aims to investigate the role of oxidative stress in NASH development and progression. By targeting the MAP kinases p38 and JNK, which drive the inflammatory and fibrotic aspects of NASH, our research could lead to new treatment approaches.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Kobenhavns Universitet | Kobenhavn | Denmark | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI